<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03766308</url>
  </required_header>
  <id_info>
    <org_study_id>TJ-NFM-0001</org_study_id>
    <nct_id>NCT03766308</nct_id>
  </id_info>
  <brief_title>The Clinical Study of the Effect of Highland Barley Diet on Blood Glucose in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>The Clinical Study of the Effect of Highland Barley Diet on Blood Glucose in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuefeng Yu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study of the effect of highland barley diet on blood glucose in patients with
      type 2 diabetes mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical study of the effect of highland barley diet on blood glucose in patients with
      type 2 diabetes mellitus.

      Approximately 40 patients will be enrolled in the study from China and randomized in a 1:1
      ratio to one of the 2 treatment arms: highland barley diet + metformin; or +common diet
      metformin.

      Study treatment will continue for 12 weeks. The primary efficacy measure is the change in
      HbA1c at 12 weeks. The study consists of 3 periods: a 1-week screening (period A), a 4-week
      run-in period (period B) and a 12-week treatment period (period C).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>from baseline to 12-week endpoint</time_frame>
    <description>In the newly diagnosed type 2 diabetic patients, the absolute value of glycosylated hemoglobin from baseline to 12-week endpoints was compared between groups in the qingke diet group and the normal diet group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants who achieved HbA1c ≤ 6.5% and &lt; 7%</measure>
    <time_frame>12 weeks</time_frame>
    <description>The percentage of participants who achieved HbA1c ≤ 6.5% and &lt; 7%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glucose</measure>
    <time_frame>6 weeks and 12weeks</time_frame>
    <description>Fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Blood Glucose</measure>
    <time_frame>6 weeks and 12weeks</time_frame>
    <description>Postprandial blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7 point self-monitoring blood sugar</measure>
    <time_frame>from baseline to 6 and 12 weeks</time_frame>
    <description>7 point self-monitoring blood sugar</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood lipid</measure>
    <time_frame>from baseline to 6 and 12 weeks</time_frame>
    <description>blood lipid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>uric acid</measure>
    <time_frame>from baseline to 6 and 12 weeks</time_frame>
    <description>uric acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance index</measure>
    <time_frame>0weeks and 12weeks</time_frame>
    <description>Insulin resistance index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta cell function index of islet</measure>
    <time_frame>0weeks and 12weeks</time_frame>
    <description>Beta cell function index of islet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>from baseline to 12 weeks</time_frame>
    <description>Change in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist circumference</measure>
    <time_frame>from baseline to 12 weeks</time_frame>
    <description>Change in Waist circumference</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Highland barley diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>highland barley diet(20g, thrice-daily) +Metformin sustained-release tablets(500mg, thrice-daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADA diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ADA diet + Metformin sustained-release tablets(500mg, thrice-daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Highland Barley Diet</intervention_name>
    <description>Highland Barley Diet</description>
    <arm_group_label>Highland barley diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ADA diet</intervention_name>
    <description>ADA diet</description>
    <arm_group_label>ADA diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent

          2. Type 2 diabetic patients （new diagnose ）

          3. HbA1c ≥7.0 % and &lt; 9.0 % (HbA1c &gt; 7.0 % and ≤ 8.0% at randomization)

          4. Men and women (non-pregnant and using a medically approved birth-control method) aged
             ≥ 18 and ≤ 70 years

          5. BMI ≥ 23 and ≤ 35 kg/m2

        Exclusion Criteria:

          1. Type 1 diabetes or other specific types of diabetes

          2. Pregnancy, preparation for pregnancy, lactation and women of child-bearing age
             incapable of effective contraception methods

          3. Uncooperative subject because of various reasons

          4. Abnormal liver function, glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic
             transaminase (AST) ＞ twice the upper limits of normal

          5. Impairment of renal function, serum creatinine: ≥ 133mmol/L for female，≥ 135mmol/L for
             male

          6. Serious chronic gastrointestinal diseases

          7. Edema

          8. Serious heart diseases, such as cardiac insufficiency (level III or more according to
             NYHA), acute coronary syndrome and old myocardial infraction

          9. Blood pressure: Systolic blood pressure (SBP) ≥ 180mmHg and/or diastolic blood
             pressure (DBP) ≥ 110mmHg

         10. White blood count (WBC) ＜ 4.0×109/L or platelet count (PLT) ＜ 90×109/L，or definite
             anemia (Hb：＜ 120g/L for male, ＜ 110g/L for female), or other hematological diseases

         11. Endocrine system diseases, such as hyperthyroidism and hypercortisolism

         12. Experimental drug allergy or frequent hypoglycemia

         13. Psychiatric disorders, drug or other substance abuse

         14. Diabetic ketoacidosis and hyperosmolar nonketotic coma requiring insulin therapy

         15. Stressful situations such as surgery, serious trauma and so on

         16. Chronic hypoxic diseases such as pulmonary emphysema and pulmonary heart disease

         17. Combined use of drugs effecting glucose metabolism such as glucocorticoid Tumor,
             especially bladder tumor and/or family history of bladder tumor and/or long-term
             hematuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xi Chen</last_name>
    <phone>86+13667217301</phone>
    <email>amazingamycx@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Chen, doctor</last_name>
      <phone>86+13667217301</phone>
      <email>amazingamycx@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 29, 2017</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2018</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xuefeng Yu</investigator_full_name>
    <investigator_title>Director of Department of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>highland barley diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

